112 PBAC submissions on file, active 2005–2025. 76% have been recommended.
Submissions
112
2005 → 2025
Win rate
76 %
85 recommended of 112 bucketable
Drugs
36 · 30 listed
unique molecules submitted
PBS spend captured
$455M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
1×Application of 19.4% CLL incidence growth rate to R/R patient numbers was inappropriate as AIHW incidence figures do not directly relate to R/R patients
1×PBS data showed 7% decline in first initiators over the comparison period
1×claim of 27% sequential venetoclax use was not substantiated (actual data showed 3.7% venetoclax use post-BTKi)
1×PBAC rejected the requested restriction changes because the data system does not allow the terminology change from 'condition' to 'disease' as requested
1×further consideration was deferred pending Department recommendations on third-line T2DM restriction amendments.